Basel, Switzerland-headquartered Sandoz has signed an agreement to acquire US rights to Cimerli, a biosimilar of Roche and Novartis’ ophthalmology therapy Lucentis (ranibizumab), from Coherus ...

Coherus BioSciences Inc (NASDAQ:CHRS) shares are trading higher after the company agreed to divest its Cimerli ophthalmology franchise to Sandoz Group AG (OTC:SDZNY) (OTC:SDZXF) for $170 million ...